NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines

Table 1

N-glycosylated (NGc) ganglioside-based cancer vaccines.

Vaccine	Product description	Target antigen	Potential indications	Clinical Phase
Racotumomab	Anti-idiotype murine mAb (1E10 antibody)	NGc-containing gangliosides	Lung cancer Breast cancerPediatric tumors?	Ongoing Phase III
NGcGM3/VSSP	Ganglioside conjugated with bacterial proteoliposomes	NGcGM3 ganglioside	Breast cancer Melanoma Sarcoma?	Ongoing Phase III